SAN FRANCISCO (MarketWatch) -- AstraZeneca PLC said Monday that results from a one-year study show that patients taking its Symbicort single-inhaler therapy had fewer asthma attacks and required less ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback